Baipharm
ChemLinkedMarketChemicalFoodCosmeticBaiPharm Agrochemical Japan
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
POLICY
Volume-Based Procurement
China Kicks off the 7th Round of Volume-based Procurement (VBP) of Drugs On June 20, China National Joint Drug Procurement Office announced the start of the 7th round of volume-based procurement (VBP), covering 59 drugs with different active pharmaceutical ingredients.
Jun 24, 2022
INDUSTRY
NRDL Volume-Based Procurement Medical Insurance Innovative Drug Generic Drug Biosimilar New Drug COVID-19
Multinational Pharma Companies Record Sales Growth in 2021 Johnson & Johnson ranks the first with global sales of 93.77 billion USD. Pfizer has the most rapid growth in global sales, zooming up by 95% to 81.3 billion USD. AstraZeneca is the largest foreign pharma company regarding its 5.99 billion USD sales in China. MSD records the most vigorous sales growth in China of 60%, bringing the sales to 4.26 billion USD.
Mar 18, 2022
POLICY
Law & Regulation Marketing Approval Volume-Based Procurement Medical Insurance Innovative Drug Cancer Cardiovascular Disease Rare Disease Drug Registration New Drug
China's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022
REGULATION
Law & Regulation Marketing Approval Clinical Trial Priority Review and Approval NRDL Volume-Based Procurement Medical Insurance Innovative Drug API Rare Disease New Drug
The 15th Rare Disease Day: China's Policy & Market Overview China tries to make rare disease drugs available to more patients via measures like expediting the marketing approval of the drugs and reimbursing part of the medical expenses. Meanwhile, the rare disease treatment market is expanding rapidly.
Mar 04, 2022
REGULATION
Law & Regulation CDE Guideline Reference Listed Drug (RLD) Marketing Approval Clinical Trial Volume-Based Procurement Generic Drug Biosimilar New Drug
Monthly Recap: China Pharmaceutical Regulatory Updates | January 2022 1. China Pilots Online Sales of Prescription Drugs in Shenzhen; 2. National Insulin Procurement to Start in May; 3. China NMPA Grants Two Rx-to-OTC Switches; 4. China NMPA Releases the 50th Batch of Reference Listed Drugs; 5. China NMPA Approves 221 Medical Devices; 6. China NMPA Issues Three Industry Standards for Medical Devices; 7. Pharmaceutical Guidelines.
Feb 10, 2022
REGULATION
Law & Regulation Pharmacopoeia MAH Pharmacovigilance Marketing Approval Priority Review and Approval Volume-Based Procurement
Top 10 BaiPharm Stories of China's Pharmaceutical Regulations | 2021 Recep ChemLinked BaiPharm Portal has been delivering and decoding China's pharmaceutical regulations to help international drug makers access the Chinese market. Here are the 10 regulatory topics that our readers are most concerned about in 2021.
Jan 07, 2022
REGULATION
Law & Regulation Reference Listed Drug (RLD) MAH Marketing Approval Volume-Based Procurement
Monthly Recap: China Pharmaceutical Regulatory Updates | November 2021 1. China Insulin VBP Tender Result; 2. NMPA Launches Drug Supply Information Submission System; 3. NMPAs Requires Documentation for Import/Export Permit of Analgesics and Antipsychotics; 4. NMPA Announces One Rx-to-OTC Switch; 5. The 48th Batch of Reference Listed Drugs; 6. NMPA Approves 110 Medical Devices; 7. NHC Releases Administrative Measures for National Essential Medicine List (Revised Draft); 8. NMPA Releases Administrative Measures for Quality Supervision in Drug Supply, Distribution and Use (Consultation Draft)...
Dec 16, 2021
POLICY
Volume-Based Procurement Biological Product
China's Insulin VBP Saw Average Price Cut of 48.75% China’s insulin VBP (volume-based procurement)--eleven drug makers won the bid to supply insulin products to public healthcare institutions across China. Among 42 bid-winner products, Novo Nordisk took the champion with seven products. Two local Chinese companies—Gan & Lee and the United Laboratories—took the second and third places with six products respectively.
Dec 06, 2021
POLICY
Volume-Based Procurement
A Record Number of Foreign Companies Win Bidding for China's 5th VBP of Drugs 251 products from 148 companies won the bidding on June 23 in Shanghai for the latest and fifth round of China’s national centralized drug procurement. The bidding saw some record numbers. One of them is the unprecedented number of 10 international pharma companies successfully earning places in the procurement program.
Jun 30, 2021
POLICY
Volume-Based Procurement
Data Analysis: What "4+7" Procurement Has Brought to China Drug Market The “4+7” procurement program opens a gate to a larger market for some drug products. But larger sales volume does not necessarily mean higher sales revenue.
May 31, 2021
12 Next
Most Popular